Dosage and placebo comparison (CD17 vs CD12 ) P
Post# of 148148
Patients will be randomized in a 1:1 ratio to receive up to four doses of leronlimab (PRO 140) or placebo. Leronlimab (700 mg followed by 350 mg weekly) or placebo will be administered subcutaneously over a 4-week treatment period. No treatments will be administered post-discharge.
CD17: Day 0 -- 700 mg.
Day 7 350+350=700.
Day 14 350+350=700
Day 21 350+350=700
Day 28 350
CD 12 Day 0 -- 700 mg
Day 7 -- 350+700= 1050 mg
Day 14-- 525 mg
Day 21 -- 260 mg
Day 28-- 130 mg
Placebo
CD 17-- SOC
CD. 12-- SOC
Exclusions
CD 17 -- Participants who are immunocompromised, with known immunodeficiencies, or taking potent immunosuppressive agents (e.g., azathioprine, cyclosporine).
Question: Can dexamethasone be used?
CD 12 -- no mention of immunosuppressive drugs. Dexamethasone was widely used.
I am cautiously optimistic about CD 17
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.